"Parsaclisib Has Activity in Patients with B-cell Malignancies."

LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

A next-generation PI3Kδ inhibitor achieved objective responses and long-term tolerability in NHL. Click to show full abstract

A next-generation PI3Kδ inhibitor achieved objective responses and long-term tolerability in NHL.

Keywords: parsaclisib activity; cell malignancies; patients cell; activity patients

Journal Title: Cancer discovery
Year Published: 2019

Link to full text (if available)

Share on Social Media: Sign Up to like & get
recommendations!
0

LAUSR

You are not signed in:

Sign Up!

Related content

More Information News Social Media Video Recommended